Glaxo plc; Prohibited Trade Practices, and Affirmative Corrective Actions

FEDERAL TRADE COMMISSION

[Dkt. C-3586]

Glaxo plc; Prohibited Trade Practices, and Affirmative Corrective

Actions

AGENCY: Federal Trade Commission.

ACTION: Consent order.

-----------------------------------------------------------------------

SUMMARY: In settlement of alleged violations of federal law prohibiting

unfair acts and practices and unfair methods of competition, this

consent order requires, among other things, a British drug company to

divest, within nine months, Wellcome's worldwide research and

development assets for non-injectable drugs, or else agree to have a

Commission-appointed trustee to complete the transaction. In addition,

the consent order requires Glaxo, for a period of ten years, to obtain

Commission approval before acquiring more than one percent interest in

any entity involved in the clinical development, manufacture or sale of

migraine drugs.

DATES: Complaint and Order issued June 14, 1995.\1\

\1\ Copies of the Complaint and the Decision and Order are

available from the Commission's Public Reference Branch, H-130, 6th

Street & Pennsylvania Avenue, NW., Washington, DC 20580.

---------------------------------------------------------------------------

FOR FURTHER INFORMATION CONTACT:

Claudia Higgins or Ann Malester, FTC/S-2224, Washington, DC 20580.

(202) 326-2682.

SUPPLEMENTARY INFORMATION: On Wednesday, March 29, 1995, there was

published in the Federal Register, 60 FR 16139, a proposed consent

agreement with analysis In the Matter of Glaxo plc, for the purpose of

soliciting public comment. Interested parties were given sixty (60)

days in which to submit comments, suggestions or objections regarding

the proposed form of the order.

No comment have been received, the Commission has ordered the

issuance of the complaint in the form contemplated by the agreement,

made its jurisdictional findings and entered an order to divest, as set

forth in the proposed consent agreement, in disposition of this

proceeding.

(Sec. 6, Stat. 721; 15 U.S.C. 46. Interpret or apply sec. 5, 38

Stat. 719, as amended; sec. 7, 38 Stat. 731, as amended; 15 U.S.C.

45, 18)

Benjamin I. Berman,

Acting Secretary.

[FR Doc. 95-18953 Filed 8-1-95; 8:45 am]

BILLING CODE 6750-01-M